A practical reference on WADA: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
== Clinical significance == The Wnt signaling pathway was first linked to bone development when a loss-of-function mutation in LRP5 was found to cause osteoporosis-pseudoglioma syndrome. Shortly thereafter, two studies reported that gain-of-function mutations in LRP5 caused high bone mass. Many bone density related diseases are caused by mutations in the LRP5 gene. There is controversy whether bone grows through Lrp5 through bone or the intestine. The majority of the current data supports the concept that bone mass is controlled by LRP5 through the osteocytes. Mice with the same Lrp5 gain-of-function mutations also have high bone mass. The high bone mass is maintained when the mutation only occurs in limbs or in cells of the osteoblastic lineage. Bone mechanotransduction occurs through Lrp5 and is suppressed if Lrp5 is removed in only osteocytes. There are promising osteoporosis clinical trials targeting sclerostin, an osteocyte-specific protein which inhibits Wnt signaling by binding to Lrp5. An alternative model that has been verified in mice and in humans is that Lrp5 controls bone formation by inhibiting expression of TPH1, the rate-limiting biosynthetic enzyme for serotonin, a molecule that regulates bone formation, in enterochromaffin cells of the duodenum and that excess plasma serotonin leads to inhibition in bone. Another study found that a different Tph1-inhibitor decreased serotonin levels in the blood and intestine, but did not affect bone mass or markers of bone formation.
=== 2025 === In January 2025, before taking office, Trump stated he would not exclude using economic or military force against Greenland and that the United States needed the territory for national security. On 6 January 2025, he threatened to "tariff Denmark at a very high level" if it did not agree to Trump's plan. On 11 January, Donald Trump Jr. went on a private visit to Greenland. Local media reported that his entourage passed out MAGA hats to locals and attempted to speak to residents on a speakerphone. Pipaluk Lynge, a Greenlandic member of parliament, called the visit "staged". Berlingske reported that an American military person asked the Joint Arctic Command to provide information about Greenlandic infrastructure. In the following months, Republican congressman Buddy Carter introduced a bill in the United States Congress to advance efforts to annex Greenland and rename it Red, White, and Blueland and US vice president JD Vance visited, without invitation, the Pituffik Space Base, where he gave a speech about how Denmark had failed Greenlanders. Vance's visit was condemned by Greenlandic and Danish politicians, and described as a provocation. In connection with the visit, commander Susannah Meyers, the highest-ranking US officer in Greenland, said the Trump administration's threats against the Kingdom of Denmark "are not reflective of Pituffik Space Base". In response, Meyers was fired by Trump.
Hypomobility is reduced range of motion in one or more joints relative to what is considered normal. It may arise from structural, neurological, inflammatory, or functional causes, and may be temporary or chronic depending on the underlying condition. Hypomobility is commonly assessed in clinical contexts such as musculoskeletal medicine, physiotherapy, and rheumatology.
=== Engine coolant standards === The Volkswagen Group has been particularly committed to the development of coolants and their standards (VW TL 774) in collaboration with Haertol Chemie from Magdeburg. VW standards include: G11, G12, G12+, G12++, G13 and G12evo. Another company involved in the development is BASF (Glysantin), whose standards are: G30, G40, G48, G05, G33, and G34. Volkswagen Group:
Sources: en.wikipedia.org
and a million and a half dwellings and over 105 square miles (270 km2) of urban space were destroyed." In Tokyo, Osaka and Nagoya, "the areas leveled (almost 100 square miles (260 km2)) exceeded the areas destroyed in all German cities by both the American and British air forces (about 79 square miles (200 km2))." P-51s also conducted a series of independent ground-attack missions against targets in the home islands. The first of these operations took place on 16 April, when 57 P-51s strafed Kanoya Air Field in Kyushu. In operations conducted between 26 April and 22 June, the American fighter pilots claimed the destruction of 64 Japanese aircraft and damage to another 180 on the ground, as well as a further 10 shot down in flight; these claims were lower than the American planners had expected, however, and the raids were considered unsuccessful. USAAF losses were 11 P-51s to enemy action and seven to other causes. Due to the lack of Japanese air opposition to the American bomber raids, VII Fighter Command was solely tasked with ground-attack missions from July. These raids were frequently made against airfields to destroy aircraft being held in reserve to attack the expected Allied invasion fleet. While the P-51 pilots only occasionally encountered Japanese fighters in the air, the airfields were protected by antiaircraft batteries and barrage balloons. By the end of the war, VII Fighter Command had conducted 51 ground-attack raids, of which 41 were considered successful.
==== Physical health ==== Meta-analyses published between 2013 and 2017 show that exercise is associated with reductions in depressive symptoms, fatigue and QoL plus improvements in attention, hyperactivity, impulsivity, social functioning, schizophrenic symptoms, and verbal fluency in various special populations. However, aerobic exercise has no significant effect on anxiety disorders. In 2005 a study conducted by Andrew Steptow and Michael Marmot at University College London, found that happiness is related to biological markers that play an important role in health. The researchers aimed to analyze whether there was any association between well-being and three biological markers: heart rate, cortisol levels, and plasma fibrinogen levels. The participants who rated themselves the least happy had cortisol levels that were 48% higher than those who rated themselves as the most happy. The least happy subjects also had a large plasma fibrinogen response to two stress-inducing tasks: the Stroop test, and tracing a star seen in a mirror image. Repeating their studies three years later Steptow and Marmot found that participants who scored high in positive emotion continued to have lower levels of cortisol and fibrinogen, as well as a lower heart rate. In Happy People Live Longer (2011), Bruno Frey reported that happy people live 14% longer, increasing longevity 7.5 to 10 years and Richard Davidson's bestseller (2012) The Emotional Life of Your Brain argues that positive emotion and happiness benefit long-term health.
H2N-CO-NH2 → HNCO + NH3 H2N-CO-NH2 + HNCO → H2N-CO-NH-CO-NH2 H2N-CO-NH-CO-NH2 + HNCO → H2N-CO-NH-CO-NH-CO-NH2 As temperature exceeds 190 °C (374 °F), other reactions begin to dominate the process. The first appearance of ammeline occurs prior to 225 °C (437 °F) and is suspected also to occur from decomposition of biuret but is produced at a lower rate than that of CYA or ammelide.
Sources: en.wikipedia.org
A scavenger in chemistry is a chemical substance added to a mixture in order to remove or de-activate impurities and unwanted reaction products, for example oxygen, to make sure that they will not cause any unfavorable reactions. Their use is wide-ranged:
=== Short-term effects === Insufflating (snorting) cocaine commonly causes increased mucus production due to irritation and inflammation of the nasal passages. This irritation leads to symptoms such as a runny nose, nasal congestion, and excessive or thickened mucus. Acute exposure to cocaine has many effects on humans, including euphoria, increases in heart rate and blood pressure, and increases in cortisol secretion from the adrenal gland. In humans with acute exposure followed by continuous exposure to cocaine at a constant blood concentration, the acute tolerance to the chronotropic cardiac effects of cocaine begins after about 10 minutes, while acute tolerance to the euphoric effects of cocaine begins after about one hour. With excessive or prolonged use, the drug can cause itching, fast heart rate, and paranoid delusions or sensations of insects crawling on the skin. Cocaine can induce psychosis characterized by paranoia, impaired reality testing, hallucinations, irritability, and physical aggression. Cocaine intoxication can cause hyperawareness, hypervigilance, psychomotor agitation, and delirium. Consumption of large doses of cocaine can cause violent outbursts, especially by those with preexisting psychosis. Acute exposure may induce arrhythmia, including atrial fibrillation, supraventricular tachycardia, ventricular tachycardia, and ventricular fibrillation. Acute exposure may also lead to angina, heart attack, and congestive heart failure.
(February 2, 2016), "Forensic Chemistry and Ambient Mass Spectrometry: A Perfect Couple Destined for a Happy Marriage?", Analytical Chemistry, 88 (5), American Chemical Society (ACS): 2515–2526, doi:10.1021/acs.analchem.5b02397, ISSN 0003-2700, PMID 26768158 Wu, Chunping; Dill, Allison L.; Eberlin, Livia S.; Cooks, R. Graham; Ifa, Demian R. (September 20, 2012), "Mass spectrometry imaging under ambient conditions", Mass Spectrometry Reviews, 32 (3), Wiley: 218–243, doi:10.1002/mas.21360, ISSN 0277-7037, PMC 3530640, PMID 22996621 Eberlin, Livia S.; Norton, Isaiah; Orringer, Daniel; Dunn, Ian F.; Liu, Xiaohui; Ide, Jennifer L.; Jarmusch, Alan K.; Ligon, Keith L.; Jolesz, Ferenc A.; Golby, Alexandra J.; Santagata, Sandro; Agar, Nathalie Y. R.; Cooks, R. Graham (January 8, 2013), "Ambient mass spectrometry for the intraoperative molecular diagnosis of human brain tumors", Proceedings of the National Academy of Sciences, 110 (5): 1611–1616, Bibcode:2013PNAS..110.1611E, doi:10.1073/pnas.1215687110, ISSN 0027-8424, PMC 3562800, PMID 23300285 Eberlin, Livia S.; Norton, Isaiah; Dill, Allison L.; Golby, Alexandra J.; Ligon, Keith L.; Santagata, Sandro; Cooks, R. Graham; Agar, Nathalie Y.R. (January 31, 2012), "Classifying Human Brain Tumors by Lipid Imaging with Mass Spectrometry", Cancer Research, 72 (3), American Association for Cancer Research (AACR): 645–654, doi:10.1158/0008-5472.can-11-2465, ISSN 0008-5472, PMC 3271168, PMID 22139378
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.